Fallopian Tube Cancer Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Clinical Trials

A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Condition:   Neoplasms, Ovarian Interventions:   Drug: MORAb-202;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin (PLD);   Drug: Topotecan Sponsor:   Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 14, 2022 Category: Research Source Type: clinical trials

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Conditions:   Platinum-Resistant Fallopian Tube Carcinoma;   Platinum-Resistant Primary Peritoneal Carcinoma;   PARP Inhibitor;   Hedgehog Inhibitor Interventions:   Drug: Vismodegib;   Drug: Atezolizumab Sponsors:   Ronald Buckanovich;   Genentech, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2022 Category: Research Source Type: clinical trials